Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Author:
Publisher
China Science Publishing & Media Ltd.
Subject
General Medicine
Link
https://engine.scichina.com/doi/pdf/C012380D285843AABF428E81C4188CE6
Reference18 articles.
1. DHAKAL B, HARI P N, USMANI S Z. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges[J]. Bone Marrow Transplant, 2021, 56: 9-19.
2. ZHANG M, ZHOU L, ZHAO H. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy[J]. Clin Cancer Res, 2021, 27: 6384-6392.
3. NEELAPU S S, TUMMALA S, KEBRIAEI P. Chimeric antigen receptor T-cell therapy——assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15: 47-62.
4. HASHMI H, BACHMEIER C, CHAVEZ J C. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy[J/OL]. Br J Haematol, 2019, 187:
5. LICHTENSTEIN D A, SCHISCHLIK F, SHAO L. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells[J]. Blood, 2021, 138: 2469-2484.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma;Transplantation and Cellular Therapy;2024-09
2. Challenges and innovations in CAR-T cell therapy: a comprehensive analysis;Frontiers in Oncology;2024-06-11
3. From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma;Heliyon;2024-05
4. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities;Transplantation and Cellular Therapy;2024-01
5. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)–associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy;Cytotherapy;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3